feedburner

Enter your email address:

Delivered by FeedBurner

Biocon, Mylan win US court ruling in favour of insulin Glargine

US District Court of New Jersey found the device patent claims (US
Patent No. 9526844) asserted by Sanofi against Biocon and Mylan's
insulin Glargine product 'not infringed' and 'invalid' for lack of
written description, said Biocon in a press statement. Semglee is
co-developed with Mylan in the US.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biocon-mylan-win-us-court-ruling-that-nullifies-sanofis-patent/articleshow/74580213.cms



0 comments:

Post a Comment